Biomarkers for clinical outcome among patients with advanced or metastatic NSCLC treated with pembrolizumab alone or in combination with chemotherapy

被引：0
|
作者：
Abed, Afaf [1 ,2 ,3 ]
Beasley, Aaron [1 ,2 ]
Reid, Anna [1 ,2 ]
Law, Nc [4 ]
Leslie, Calapre [1 ,2 ]
Michael, Millward [3 ]
Johnny, Lo [1 ]
Elin, Gray [1 ,2 ]
机构：
[1] Edith Cowan Univ, Sch Sci, Joondalup, Australia
[2] Edith Cowan Univ, Sch Med & Hlth Sci, Joondalup, Australia
[3] Univ Western Australia, Sch Med, Crawley, Australia
[4] Sir Charles Gairdner Hosp, Dept Med Oncol, Nedlands, WA, Australia
来源：
RESPIROLOGY | 2023年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
34
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [1] Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront
    Jimenez, J. Torres
    Gorria, T.
    Auclin, E.
    Castro, N.
    Albarran-Artahona, V.
    Ruffinelli, J. C.
    Pinato, D.
    Routy, B.
    Nana, F. Aboubakar
    Reyes, R.
    Vinolas, N.
    Blanc-Durand, F.
    Lopes, G.
    Nadal, E.
    Arasanz, H.
    Pascal, M.
    Teixido, C.
    Besse, B.
    Reguart, N.
    Mezquita, L.
    Jimenez, J. Torres
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S385 - S386
  • [2] Outcome predictors for pembrolizumab alone or with chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Zullo, L.
    Cella, E.
    Paoloni, F.
    Gualtieri, M.
    Barletta, G.
    Favero, D.
    Parisi, F.
    Dellepiane, C.
    Rossi, G.
    Bennicelli, E.
    Zinoli, L.
    Cantini, L.
    Pecci, F.
    Del Mastro, L.
    Berardi, R.
    Genova, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S78 - S79
  • [3] Exploration of serum biomarkers predicting clinical outcome and irAEs in advanced NSCLC patients treated with nivolumab
    Oyanagi, Jun
    Koh, Yasuhiro
    Sato, Koichi
    Kanai, Kuninobu
    Hayata, Atsushi
    Akamatsu, Hiroaki
    Tokudome, Nahomi
    Akamatsu, Keiichiro
    Nakanishi, Masanori
    Ueda, Hiroki
    Yamamoto, Nobuyuki
    CANCER SCIENCE, 2018, 109 : 1428 - 1428
  • [4] A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab
    Awada, Gil
    Jansen, Yanina
    Schwarze, Julia Katharina
    Tijtgat, Jens
    Hellinckx, Lennert
    Gondry, Odrade
    Vermeulen, Sim
    Warren, Sarah
    Schats, Kelly
    van Dam, Pieter-Jan
    Kockx, Mark
    Keyaerts, Marleen
    Everaert, Hendrik
    Seremet, Teofila
    Rogiers, Anne
    Neyns, Bart
    CANCERS, 2021, 13 (02) : 1 - 18
  • [5] Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
    Chen, Ya
    Yang, Zhengyu
    Wang, Yanan
    Hu, Minjuan
    Zhang, Bo
    Zhang, Yanwei
    Qian, Fangfei
    Zhang, Wei
    Han, Baohui
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [6] Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab A Phase 2 Clinical Trial
    Kelly, Ciara M.
    Antonescu, Cristina R.
    Bowler, Timothy
    Munhoz, Rodrigo
    Chi, Ping
    Dickson, Mark A.
    Gounder, Mrinal M.
    Keohan, Mary Louise
    Movva, Sujana
    Dholakia, Reena
    Ahmad, Hamza
    Biniakewitz, Matthew
    Condy, Mercedes
    Phelan, Haley
    Callahan, Margaret
    Wong, Phillip
    Singer, Sam
    Ariyan, Charlotte
    Bartlett, Edmund K.
    Crago, Aimee
    Yoon, Sam
    Hwang, Sinchun
    Erinjeri, Joseph P.
    Qin, Li-Xuan
    Tap, William D.
    D'Angelo, Sandra P.
    JAMA ONCOLOGY, 2020, 6 (03) : 402 - 408
  • [7] Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
    Weide, Benjamin
    Martens, Alexander
    Hassel, Jessica C.
    Berking, Carola
    Postow, Michael A.
    Bisschop, Kees
    Simeone, Ester
    Mangana, Johanna
    Schilling, Bastian
    Di Giacomo, Anna Maria
    Brenner, Nicole
    Kaehler, Katharina
    Heinzerling, Lucie
    Gutzmer, Ralf
    Bender, Armin
    Gebhardt, Christoffer
    Romano, Emanuela
    Meier, Friedegund
    Martus, Peter
    Maio, Michele
    Blank, Christian
    Schadendorf, Dirk
    Dummer, Reinhard
    Ascierto, Paolo A.
    Hospers, Geke
    Garbe, Claus
    Wolchok, Jedd D.
    CLINICAL CANCER RESEARCH, 2016, 22 (22) : 5487 - 5496
  • [8] Pembrolizumab as a Monotherapy or in Combination With Platinum-Based Chemotherapy in NSCLC: Correlation With Blood Biomarkers
    Holtzman, L.
    Moskovitz, M.
    Urban, D.
    Wollner, M.
    Nechushtan, H.
    Rainhorn, D.
    Zer, A.
    Shochat, T.
    Bar, J.
    Rottenberg, Y.
    Dudnik, E.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S964 - S964
  • [9] Pembrolizumab in Combination with Chemotherapy for Patients with metastatic NSCLC: An Analysis using Real-World Data from the National Clinical Cancer Registry
    Haberlin, J.
    Kanz, F.
    Surovtsova, I
    Morakis, P.
    PNEUMOLOGIE, 2024, 78 : S100 - S101
  • [10] T Cell Receptor Diversity among Non-Small Cell Lung Cancer Patients Treated with Pembrolizumab Alone or in Combination with Chemotherapy
    Abed, A.
    Beasly, A.
    Reid, A.
    Calapre, L.
    Millward, M.
    Gray, E.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S555 - S556
12345